Main Menu
Search

3 October 2013

The price is life for vital HIV test

Paving the way for better HIV treatment in the world’s least-developed countries

Cambridge Consultants is working with Médecins Sans Frontières (MSF) to help support moves to expand access to vital diagnostic tests, which paves the way for better treatment of HIV in some of the world’s least-developed countries.

The product development and technology consulting firm is helping MSF’s efforts to widen access to HIV viral load tests by exploring the relative costs of the technologies underpinning a range of viral load assays. These tests are designed for HIV-infected patients undergoing antiretroviral therapy and measure the number of HIV viral particles in patients’ blood.

Viral load testing is the gold standard for HIV treatment monitoring, as it can accurately and quickly detect whether antiretroviral treatment is working. Regular monitoring ensures treatment continues to be effective and patients are adhering to their therapy regime. The World Health Organisation strongly recommends the use of regular viral load monitoring in developing countries.

James Blakemore, senior consultant at Cambridge Consultants, said: “Price and complexity have so far hindered the rollout of these life-saving tests in developing countries. Our work with MSF allows us to share our understanding of the relative costs of assay technologies employed in both central laboratories and point-of-care environments.”

Teri Roberts, diagnostics adviser at MSF, said: “Viral load testing is the best way to ensure treatments are working for patients. It enables timely switching to a more effective drug regimen quickly and accurately before further drug resistance mutations accumulate and reduce the efficacy of second and third-line regimens. The test also helps keep people on more affordable drugs for as long as possible, as targeted and enhanced adherence support – triggered by a detectable viral load – may help keep patients on existing regimens. Working with Cambridge Consultants to analyse key technology options is allowing us to settle on a fair price for a high-quality viral load test.”

Cambridge Consultants is assessing the relative cost per HIV viral load test based on different technologies – analysing costs from reagents, packaging and labelling, as well as manufacturing and intellectual property considerations.

Notes to editors

Cambridge Consultants develops breakthrough products, creates and licenses intellectual property, and provides business consultancy in technology-critical issues for clients worldwide. For more than 50 years, the company has been helping its clients turn business opportunities into commercial successes, whether they are launching first-to-market products, entering new markets or expanding existing markets through the introduction of new technologies. With a team of more than 700 staff, including engineers, scientists, mathematicians and designers, in offices in Cambridge (UK), Boston (USA) and Singapore, Cambridge Consultants offers solutions across a diverse range of industries including medical technology, industrial and consumer products, digital health, oil and gas, and wireless communications.

Cambridge Consultants is part of Altran, a global leader in engineering and R&D services which offers its clients a new way to innovate. Altran works alongside its clients on every link in the value chain of their project, from conception to industrialisation. In 2015, the Altran group generated revenues of €1.945bn. With a headcount of more than 27,000 employees, Altran is present in more than 20 countries. For more information, visit www.altran.com.

Press Contacts

Corporate communications
Debbie Mayhew
PR & Communications Manager
Cambridge Consultants
+44 1223 392418
Debbie.Mayhew@CambridgeConsultants.com

European PR agency
David Vindel
Ketchum
+44 20 3755 6444
CambridgeConsultants@ketchum.com

US PR agency
Hanah Johnson
March Communications
+1 617 960 8892
CambridgeConsultants@ketchum.com